ANGIOTENSIN II ACETATE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for angiotensin ii acetate and what is the scope of patent protection?

Angiotensin ii acetate is the generic ingredient in one branded drug marketed by La Jolla Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Angiotensin ii acetate has forty-seven patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for ANGIOTENSIN II ACETATE

International Patents:	47
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	6
Patent Applications:	68
DailyMed Link:	ANGIOTENSIN II ACETATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ANGIOTENSIN II ACETATE

Generic Entry Date for ANGIOTENSIN II ACETATE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ANGIOTENSIN II ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kasr El Aini Hospital	N/A
American Lung Association	Phase 2
Johns Hopkins University	Phase 2

See all ANGIOTENSIN II ACETATE clinical trials

Pharmacology for ANGIOTENSIN II ACETATE

Drug Class	Vasoconstrictor
Physiological Effect	Vasoconstriction

Medical Subject Heading (MeSH) Categories for ANGIOTENSIN II ACETATE

Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for ANGIOTENSIN II ACETATE

C01CX	Other cardiac stimulants
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

Paragraph IV (Patent) Challenges for ANGIOTENSIN II ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GIAPREZA	Injection	angiotensin ii acetate	2.5 mg/mL	209360	1	2021-12-21

US Patents and Regulatory Information for ANGIOTENSIN II ACETATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-003	Dec 23, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-001	Dec 21, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-001	Dec 21, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-001	Dec 21, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
La Jolla Pharma	GIAPREZA	angiotensin ii acetate	SOLUTION;INTRAVENOUS	209360-001	Dec 21, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ANGIOTENSIN II ACETATE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	112546197	血管紧张素II单独或以组合方式用于治疗低血压 (Angiotensin ll alone or in combination for the treatment of hypotension)	⤷ Sign Up
Poland	2986308		⤷ Sign Up
Japan	7175506		⤷ Sign Up
Japan	6824739		⤷ Sign Up
Japan	2019501201	アンジオテンシンＩＩの投与方法	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.